Trial watch: Chemotherapy with immunogenic cell death inducers.
about
Trial WatchMechanisms of drug resistance in colon cancer and its therapeutic strategiesThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responsePrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerChloroquine and hydroxychloroquine for cancer therapyTumor immunotherapy: lessons from autoimmunityTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch:: Oncolytic viruses for cancer therapyPeptide-based vaccines for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyTrial Watch: Proteasomal inhibitors for anticancer therapyMolecular mechanisms of ATP secretion during immunogenic cell deathScreening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity SetOncogene withdrawal engages the immune system to induce sustained cancer regression.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Trial Watch: Peptide-based anticancer vaccines.Novel immune checkpoint blocker approved for the treatment of advanced melanomaCombinatorial strategies for the induction of immunogenic cell death.Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiationPrognostic and predictive value of PDL1 expression in breast cancer.PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy.Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells.A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyImmunotherapy for lung cancer: for whom the bell tolls?Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model.Immunological effects of chemotherapy in spontaneous breast cancers.Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.Immunosuppressants in cancer prevention and therapyTrial Watch: DNA vaccines for cancer therapy.Consensus guidelines for the detection of immunogenic cell death.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
P2860
Q24618653-2D5671B0-B979-4CC3-AE9A-B191E04527D8Q26738528-F34A81B8-B505-4ECD-957D-4DD15629DBC7Q26766066-99B3B32B-28F5-4B6A-B2B9-B9F901251C9FQ26795466-B4E363DC-5F81-43E5-BD0A-F0E932F0C876Q26827797-8F28510C-00DB-48B1-AB37-109F61A0D197Q26866179-46BED9AD-D079-4E98-B37C-E42CA24E11EFQ26993238-15553311-35E1-4CB9-82A0-7975F0D688D4Q26996518-23C39CA2-E362-4C0A-BEC4-BE581F3B9AC4Q27021951-1CB96463-60F7-4F9F-AA33-CF5B5C180E06Q27022312-79AAA031-9FE8-442F-B319-CC90131BD2CAQ28072347-3A5EA46F-213A-42C6-9262-16FAF02D9648Q28078725-981A8BC1-69AD-43C8-A558-E4A30C9ABC39Q28082910-1EA01603-088A-4DB6-8E9D-B8E6437D47C2Q30408773-12830E72-10B1-49DE-A281-B65917E32A43Q33776379-3B94763A-275A-4F96-BA19-C2B20190590CQ33987633-D06AAAD0-AD71-4A49-BB76-9EA955A44484Q34361976-24DCB452-EE4D-41B4-B8AE-12D4D5392C49Q34483345-E1A10D40-7130-4BA7-91CB-94111C36A8DCQ34936394-1CDADB83-0D9E-4292-B887-72DB8BAABFA7Q35535140-CB12F122-0FD6-4A34-8E2D-2FC3E1984EFEQ35591847-7C0F9617-84CE-4F4A-8894-FBA29CBAB2A5Q35741710-8622F75C-0199-4D27-9B64-811181F79488Q35955369-70ECDB2E-4898-4E8B-B3F5-90EDB042B910Q36710945-F37F5D58-2282-4CCF-9FA6-3C41585955A5Q36887833-82AB6E03-EB2E-4E0F-BC93-B3F048A8D732Q37028031-D2249FE7-1E79-403D-A93C-7EA56535C531Q37289086-4C215FBD-9714-4D1E-9522-28F781AC90A6Q37364980-92AC054F-6536-45E3-AFFF-592180832365Q37482728-F4FC0776-3647-4C78-8C21-1C1A3AB2BE68Q37652790-ABFE8411-D63F-4DAC-B074-477A7E6EFF5BQ38367414-1FEFE230-E18E-4491-BA14-49161D193C17Q38525024-B92769B9-940A-4619-A65D-21D02B4F2734Q38848418-F294185F-F5C6-478D-8BBF-20A35C4FD0DDQ41870388-540F665C-4FC1-416C-9B8F-36A2DEFFB7ABQ42291172-808B2AAC-F1A3-40A6-BE68-4B254D3AFFCEQ42380935-C1808C7C-EA7B-421B-B39B-C24D171E1E92Q42505783-0A625760-7FD9-4304-94DA-5585F9FCFFF7Q42552005-ABE7EF15-88D1-4019-B9BF-D5E5374469EDQ42553556-07A601FC-2AB3-44F2-A7AA-957E55146B1EQ42558833-699AB717-073E-4FF8-99F4-9FF1DD7D3990
P2860
Trial watch: Chemotherapy with immunogenic cell death inducers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Trial watch: Chemotherapy with immunogenic cell death inducers.
@en
Trial watch: Chemotherapy with immunogenic cell death inducers.
@nl
type
label
Trial watch: Chemotherapy with immunogenic cell death inducers.
@en
Trial watch: Chemotherapy with immunogenic cell death inducers.
@nl
prefLabel
Trial watch: Chemotherapy with immunogenic cell death inducers.
@en
Trial watch: Chemotherapy with immunogenic cell death inducers.
@nl
P2860
P50
P356
P1433
P1476
Trial watch: Chemotherapy with immunogenic cell death inducers.
@en
P2093
Alexander Eggermont
P2860
P304
P356
10.4161/ONCI.23510
P50
P577
2013-03-01T00:00:00Z